Education
About Us
Working with TipRanks
Follow Us
Biohaven Ltd. (BHVN)
NYSE:BHVN
BHVN Stock Chart & Stats
$11.84
-$0.59(-1.49%)
At close: 4:00 PM EST
$11.84
-$0.59(-1.49%)
Day’s Range― - ―
52-Week Range$7.48 - $44.28
Previous CloseN/A
Volume146.24K
Average Volume (3M)3.01M
Market Cap
$1.61B
Enterprise Value$1.71B
Total Cash (Recent Filing)$260.22M
Total Debt (Recent Filing)$314.18M
Price to Earnings (P/E)―
Beta1.51
Next Earnings
Mar 19, 2026EPS Estimate
-1.18Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.64
Shares Outstanding145,188,490
10 Day Avg. Volume3,630,820
30 Day Avg. Volume3,014,342
Financial Highlights & Ratios
PEG Ratio-0.06
Price to Book (P/B)8.05
Price to Sales (P/S)0.00
P/FCF Ratio-5.81
Enterprise Value/Market Cap1.06
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-1.55K
Enterprise Value/Ebitda-2.17
Forecast
1Y Price Target
$15.55Price Target Upside31.33% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering14
EPS Forecast (FY)-3.09
Revenue Forecast (FY)$4.84M
Bulls Say, Bears Say
Bulls Say
Immune‑targeted Program AdvancementAn immune‑targeted degrader program demonstrated strong reductions in disease‑related antibodies and is being advanced into expanded trials with plans toward a pivotal study, offering a potential new value driver.
Phase 3 Epilepsy ReadoutPhase 3 readout for BHV-7000 in focal onset seizures could validate the drug's efficacy and serve as a major catalyst to re-rate the stock if it shows meaningful seizure reduction.
Pipeline Prioritization And Cost OptimizationPortfolio restructuring to concentrate resources on a smaller number of late‑stage programs in immunology, obesity, and epilepsy increases focus on higher‑value assets and preserves cash for the most promising opportunities.
Bears Say
Cash Runway And Program DelaysAvailable cash is limited relative to historical spending, prompting aggressive R&D cuts and delays to lower‑priority programs that reduce the company's portfolio optionality and potential growth paths.
Efficacy And CNS Exposure Concerns For BHV‑7000A Phase 2 study for opakalim (BHV‑7000) missed its primary endpoint in major depressive disorder and ongoing questions about adequate brain exposure raise the risk that efficacy may be uncertain in future neurological trials.
Regulatory Setback For VyglxiaFDA issued a complete response letter for Vyglxia, creating major uncertainty about the drug's approval pathway and removing expected near‑term regulatory value from the company's outlook.
Biohaven Ltd. News
BHVN FAQ
What was Biohaven Ltd.’s price range in the past 12 months?
Biohaven Ltd. lowest stock price was $7.48 and its highest was $44.28 in the past 12 months.
What is Biohaven Ltd.’s market cap?
Biohaven Ltd.’s market cap is $1.61B.
When is Biohaven Ltd.’s upcoming earnings report date?
Biohaven Ltd.’s upcoming earnings report date is Mar 19, 2026 which is in 64 days.
How were Biohaven Ltd.’s earnings last quarter?
Biohaven Ltd. released its earnings results on Nov 10, 2025. The company reported -$1.64 earnings per share for the quarter, beating the consensus estimate of -$1.901 by $0.261.
Is Biohaven Ltd. overvalued?
According to Wall Street analysts Biohaven Ltd.’s price is currently Undervalued.
Does Biohaven Ltd. pay dividends?
Biohaven Ltd. does not currently pay dividends.
What is Biohaven Ltd.’s EPS estimate?
Biohaven Ltd.’s EPS estimate is -1.18.
How many shares outstanding does Biohaven Ltd. have?
Biohaven Ltd. has 145,188,490 shares outstanding.
What happened to Biohaven Ltd.’s price movement after its last earnings report?
Biohaven Ltd. reported an EPS of -$1.64 in its last earnings report, beating expectations of -$1.901. Following the earnings report the stock price went down -5.69%.
Which hedge fund is a major shareholder of Biohaven Ltd.?
Currently, no hedge funds are holding shares in BHVN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Biohaven Ltd. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$15.55 (31.33% Upside)
$15.55 (31.33% Upside)
Blogger Sentiment
Neutral
BHVN Sentiment 50%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Increased
By 1.3K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $33.1M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.9%
Last 30 Days ▼ 5.2%
Last 30 Days ▼ 5.2%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-67.75%
12-Months-Change
Fundamentals
Return on Equity
-522.08%
Trailing 12-Months
Asset Growth
-19.86%
Trailing 12-Months
Company Description
Biohaven Ltd.
Biohaven Ltd. is a clinical-stage biopharmaceutical company. The Company focuses on development of therapies for neurological and immunoscience diseases that can change current treatment paradigms.
BHVN Stock 12 Month Forecast
Average Price Target
$15.55
▲(31.33% Upside)
Technical Analysis
Ownership Overview
12.52% Insiders
11.58% Mutual Funds
20.62% Other Institutional Investors
46.46% Public Companies and
Individual Investors